{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06144697",
            "orgStudyIdInfo": {
                "id": "CN009-1024"
            },
            "organization": {
                "fullName": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants",
            "officialTitle": "A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prodrug BMS-986465 and Its Active Derivative, BMS-986464, in Healthy Participants Including Healthy Participants of Japanese Ethnicity and an Open-label Assessment of Food, Formulation, and pH Effects on the Relative Bioavailability of BMS-986465 and BMS-986464",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-the-safety-tolerability-drug-levels-food-formulation-and-ph-effects-on-relative-absorption-of-bms-and-its-active-derivative-bms-in-healthy-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03-19",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-17",
            "studyFirstSubmitQcDate": "2023-11-17",
            "studyFirstPostDateStruct": {
                "date": "2023-11-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Participants"
            ],
            "keywords": [
                "Pharmacokinetics",
                "Pharmacodynamics",
                "Healthy Participants",
                "Healthy Japanese Participants",
                "BMS-986465",
                "SAD",
                "MAD",
                "Safety",
                "Tolerability",
                "Food Effects",
                "Formulation",
                "First-in-human"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 132,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A: Single Ascending Dose (SAD) [BMS-986465 or placebo]",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986465",
                        "Other: Placebo"
                    ]
                },
                {
                    "label": "Part B: Multiple Ascending Dose (MAD) [BMS-986465 or placebo, Pegasys]",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986465",
                        "Other: Placebo",
                        "Drug: Pegasys"
                    ]
                },
                {
                    "label": "Part C: MAD in Japanese ethnicity [BMS-986465 or placebo]",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986465",
                        "Other: Placebo"
                    ]
                },
                {
                    "label": "Part D: Food/Formulation/pH Effects [BMS-986465, Famotidine]",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986465",
                        "Drug: Famotidine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BMS-986465",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part A: Single Ascending Dose (SAD) [BMS-986465 or placebo]",
                        "Part B: Multiple Ascending Dose (MAD) [BMS-986465 or placebo, Pegasys]",
                        "Part C: MAD in Japanese ethnicity [BMS-986465 or placebo]",
                        "Part D: Food/Formulation/pH Effects [BMS-986465, Famotidine]"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part A: Single Ascending Dose (SAD) [BMS-986465 or placebo]",
                        "Part B: Multiple Ascending Dose (MAD) [BMS-986465 or placebo, Pegasys]",
                        "Part C: MAD in Japanese ethnicity [BMS-986465 or placebo]"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pegasys",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part B: Multiple Ascending Dose (MAD) [BMS-986465 or placebo, Pegasys]"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Famotidine",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part D: Food/Formulation/pH Effects [BMS-986465, Famotidine]"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse events (AEs)",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Incidence of serious adverse events (SAEs)",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Number of participants with vital sign abnormalities",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Number of participants with physical examination abnormalities",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Number of participants with electrocardiogram (ECG) abnormalities",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Number of participants with clinical laboratory abnormalities",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)",
                    "timeFrame": "Up to 28 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum observed plasma concentration (Cmax)",
                    "timeFrame": "Up to Day 27"
                },
                {
                    "measure": "Time of maximum observed plasma concentration (Tmax)",
                    "timeFrame": "Up to Day 27"
                },
                {
                    "measure": "Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]",
                    "timeFrame": "Up to Day 27"
                },
                {
                    "measure": "Cerebrospinal fluid (CSF) concentrations",
                    "timeFrame": "Up to Day 27"
                },
                {
                    "measure": "Ratios of CSF to plasma concentrations",
                    "timeFrame": "Up to 9 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy male and female (i e, women not of childbearing potential) participants\n* Body Mass Index (BMI) of 18 to 32 kg\\^m2 and total body weight \u2265 50 kg\n* Parts A, B, and D: Participants without restriction on ethnicity\n* Part C: Participants of Japanese ethnicity (both biological parents are ethnically Japanese)\n\nExclusion Criteria:\n\n* Clinically significant medical, psychiatric and/or sound social reason, as determined by the investigator\n* Any major surgery within 3 months of study intervention administration\n* Participation in another clinical trial concurrent with this study\n\nNote: Other protocol-defined inclusion/exclusion criteria apply",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect Contact Center www.BMSStudyConnect.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain NCT # and Site #.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Syneos Health",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78744",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Craig Boyle, Site 0003",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "Local Institution - 0002",
                    "status": "WITHDRAWN",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84124",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/MEDWATCH/safety.htm"
                },
                {
                    "label": "BMS Clinical Trial Patient Recruiting",
                    "url": "https://www.bmsstudyconnect.com/content/studyconnect/us/en/clinical-trials/NCT06144697.html"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000100416",
                    "term": "Peginterferon alfa-2a"
                },
                {
                    "id": "D000015738",
                    "term": "Famotidine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000000897",
                    "term": "Anti-Ulcer Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000006635",
                    "term": "Histamine H2 Antagonists"
                },
                {
                    "id": "D000006633",
                    "term": "Histamine Antagonists"
                },
                {
                    "id": "D000018494",
                    "term": "Histamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M18303",
                    "name": "Famotidine",
                    "asFound": "Taxotere",
                    "relevance": "HIGH"
                },
                {
                    "id": "M247369",
                    "name": "Peginterferon alfa-2a",
                    "asFound": "Action",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4188",
                    "name": "Antacids",
                    "relevance": "LOW"
                },
                {
                    "id": "M4219",
                    "name": "Anti-Ulcer Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9708",
                    "name": "Histamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M9711",
                    "name": "Histamine H2 Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M212144",
                    "name": "Histamine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M9709",
                    "name": "Histamine Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}